Genprex, Inc.
Genprex is a clinical-stage oncology biotech with minimal political/regulatory footprint and no material government dependence.
BusinessWhat GNPX does
Genprex develops immunotherapy and gene-therapy candidates for cancer treatment, primarily in early-to-mid clinical stages. Revenue is negligible; the company is pre-commercial and funded via equity raises and grant programs. No material Medicare/Medicaid reimbursement exposure.
12 months past · 3 months futureGNPX activity timeline
Lifetime Government AwardsGNPX federal contracts
GNPX doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Politicians Trading GNPXMembers of Congress with recent GNPX positions
Congressional TradesWho in Congress is trading GNPX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere GNPX sits in Washington
Pre-commercial biotech with no lobbying footprint, no campaign donations, and no material government revenue. Stock moves on clinical trial results and financing events, not policy.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA clinical trial delays
- patent cliff risk on gene-therapy IP
Regulatory opportunities
- Orphan drug designation
- Breakthrough Therapy designation
- NIH SBIR/STTR grants
Live signals + predictions for GNPX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades GNPX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord